Consolidated Balance Sheets - USD ($) $ in Millions	Dec. 31, 2017		Dec. 31, 2016
Current Assets
Cash and cash equivalents (variable interest entity restricted - 2017: $19; 2016: $18)	$ 576		$ 638
Trade receivables - third party and affiliates (net of allowance for doubtful accounts - 2017: $9; 2016: $6; variable interest entity restricted - 2017: $5; 2016: $4)	986		801
Non-trade receivables, net	244		223
Inventories	900		720
Marketable securities, at fair value	32		30
Other assets	54		60
Total current assets	2,792		2,472
Investments in affiliates	976		852
Property, plant and equipment (net of accumulated depreciation - 2017: $2,584; 2016: $2,239; variable interest entity restricted - 2017: $697; 2016: $734)	3,762		3,577
Deferred income taxes	366		159
Other assets (variable interest entity restricted - 2017: $6; 2016: $9)	338		307
Goodwill	1,003	[1]	796
Intangible assets, net (variable interest entity restricted - 2017: $25; 2016: $26)	301		194
Total assets	9,538		8,357
Current Liabilities
Short-term borrowings and current installments of long-term debt - third party and affiliates	326		118
Trade payables - third party and affiliates	807		625
Other liabilities	354		322
Income taxes payable	72		12
Total current liabilities	1,559		1,077
Long-term debt, net of unamortized deferred financing costs	3,315		2,890
Deferred income taxes	211		130
Uncertain tax positions	156		131
Benefit obligations	585		893
Other liabilities	413		215
Commitments and Contingencies
Stockholders' Equity
Preferred stock, $0.01 par value, 100,000,000 shares authorized (2017 and 2016: 0 issued and outstanding)	0		0
Treasury stock, at cost (2017: 32,387,713 shares; 2016: 26,950,910 shares)	(2,031)		(1,531)
Additional paid-in capital	175		157
Retained earnings	4,920		4,320
Accumulated other comprehensive income (loss), net	(177)		(358)
Total Celanese Corporation stockholders' equity	2,887		2,588
Noncontrolling interests	412		433
Total equity	3,299		3,021
Total liabilities and equity	9,538		8,357
Series A common stock, $0.0001 par value, 400,000,000 shares authorized (2017: 168,156,969 issued and 135,769,256 outstanding; 2016: 167,611,357 issued and 140,660,447 outstanding)
Stockholders' Equity
Common stock	0		0
Series B common stock, $0.0001 par value, 100,000,000 shares authorized (2017 and 2016: 0 issued and outstanding)
Stockholders' Equity
Common stock	$ 0		$ 0

[1] There were $0 million of accumulated impairment losses as of December 31, 2017.